Drug profile · INN
sulfisoxazole
SULFISOXAZOLE
sulfisoxazole (SULFISOXAZOLE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — sulfisoxazole
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 0
- Data quality
- 0.84
Quick answer
sulfisoxazole (SULFISOXAZOLE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
-
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 11718591
Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof
granted -
US 11230536
Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 11034684
Isoxazole analogs as FXR agonists and methods of use thereof
granted -
US 10829486
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10752599
Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 10597391
Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10472335
Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 10450306
Isoxazole analogs as FXR agonists and methods of use thereof
granted -
US 10149836
Isoxazole treatments for frontotemporal dementia
granted -
US 10144729
Isoxazole analogs as FXR agonists and methods of use thereof
granted -
US 10138228
Isoxazole derivatives as FXR agonists and methods of use therof
granted -
US 10100021
Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 10080741
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10080742
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10080743
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 9855249
Isoxazole compounds and methods for the treatment of cystic fibrosis
granted -
US 9605000
Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
granted -
US 9271965
Crystalline forms of (R)-3-[N-(3'-chlorobiphenyl-4-ylmethyl)-N'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxyproprionic acid isopropyl ester
granted -
US 9221800
Isoxazole treatments for diabetes
granted
Frequently asked questions
What is sulfisoxazole?
sulfisoxazole (SULFISOXAZOLE) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sulfisoxazole?
SULFISOXAZOLE is a marketed brand name for sulfisoxazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sulfisoxazole?
sulfisoxazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.